New antibody-drug conjugate OK'd in DLBCL
Last Updated: Monday, May 24, 2021
The FDA granted accelerated approval to the antibody-drug conjugate (ADC) loncastuximab tesirine-lpyl for the treatment of adults with relapsed/refractory diffuse large B-cell lymphoma. The approval was based on results from the phase II LOTIS-2 trial that demonstrated an overall response rate of 48.3%, complete response rate of 24.1%, and partial response rate of 24.1% among patients who received the ADC.
Advertisement
News & Literature Highlights
